Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Th... by Schröder, Fritz H., Bangma, Chris H., Wolff, Johannes M., Alcaraz, Antonio, Montorsi, Francesco, Mongiat‐Artus, Pierre, Abrahamsson, Per‐Anders, McNicholas, Tom A., Castro, Ramiro S., Nandy, Indrani M.

Get full text

Solifenacin for Overactive Bladder: Patient-Reported Outcomes from a Large Placebo-Controlled Trial by Toglia, Marc R., Serels, Scott R., Laramee, Christine, Karram, Mickey M., Nandy, Indrani M., Andoh, Masakazu, Seifeldin, Raafat, Sergio, Forero-Schwanhaeuser

Get full text

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial by Fleshner, Neil E, Prof, Dr, Lucia, M Scott, Prof, Egerdie, Blair, FRCSC, Aaron, Lorne, FRCSC, Eure, Gregg, FACS, Nandy, Indrani, PhD, Black, Libby, PharmD, Rittmaster, Roger S, MD

Get full text

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study by Chancellor, Michael B., MD, Zinner, Norman, MD, Whitmore, Kristene, MD, Kobashi, Kathleen, MD, Snyder, Jeffrey A., MD, Siami, Paul, MD, Karram, Mickey, MD, Laramée, Christine, MD, Capo', James P., MD, Seifeldin, Raafat, PharmD, PhD, Forero-Schwanhaeuser, Sergio, MD, Nandy, Indrani, PhD

Get full text